Biopharmaceuticals from Mammalian Cells

Abstract

The advent of genetic engineering and monoclonal antibody technologies has made possible the manufacture of a wide range of pharmaceutical proteins. Many of these proteins are made in mammalian cell culture. This has required the development of novel gene-expression systems as well as technology for the large-scale culture of cells and for the isolation of proteins to exacting standards of purity. Lonza has established facilities in the UK and the USA for the contract development and manufacture of these proteins.